Phentolamine
Active ingredient · 2 therapeutic classes
- Drug class
- Imidazoline Derivatives
- Availability
- See label
- Routes
- Intravenous
- Markets covered
- 2
- Products on record
- 3
Overview
Phentolamine is an active pharmaceutical ingredient in the Imidazoline Derivatives group (C04AB). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 2 | May 15, 2026 |
| CA Canada | Health Canada | 1 | March 22, 2025 |
GBUnited Kingdom· MHRA
2 products
Uses
• Reversal of paroxysmal hypertension in pheochromocytoma before and during surgical treatment. • Diagnostic phentolamine test for the identification of pheochromocytoma when other more specific tests cannot be used or have not provided sufficient results.
How to take
CACanada· Health Canada
1 product
1 product on record with this regulator. Detailed label text (uses, dosage, side effects) is being ingested — the original document is linked under Sources [2].
Drug interactions
Known interactions involving Phentolamine. Select one for details. This list is informational and not a complete interaction checker.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PL495780038 · revised February 20, 2026
- [2]Health Canada (DPD) · 02243737 · revised March 22, 2025
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.